Latest news with #DaveRosa


Associated Press
07-07-2025
- Business
- Associated Press
Healthcare Triangle, Inc. Announces Nasdaq Hearings Panel's Grant of the Company's Request for Continued Listing of Its Securities
PLEASANTON, CALIFORNIA - July 7, 2025 ( NEWMEDIAWIRE ) - Healthcare Triangle, Inc. (Nasdaq: HCTI) ('HCTI' or the 'Company'), a visionary leader in digital transformation solutions for the healthcare and life sciences industries, today announced that the Nasdaq Stock Market (or 'Nasdaq') Hearings Panel (or 'the Company's Panel') has granted the company's request for its continued listing of the Company's securities on the Nasdaq. This decision followed a review of a Public Interest Concern raised by Nasdaq's Listing Qualifications Department. After careful consideration, the Panel determined that Healthcare Triangle Inc. is in compliance with Nasdaq's shareholders' equity rule and granted the Company a continued listing exception to resolve previously noted deficiencies. The Panel will impose a Discretionary Panel Monitor for a one-year period following any compliance determination. The Panel granted the Company's request for continued listing on the Exchange, subject to the following: 'We are elated and grateful to Nasdaq's Panel for reaching its determination, allowing us to continue with our listing intact, providing our investor base along with new investors with the ability to continue to trade our securities,' said Dave Rosa, Chairman of the Board of Directors at HCTI. 'Moving forward, we remain optimistic on advancing our mission by executing our strategic plan for maximum growth and sustainability as we empower healthcare organizations through cutting-edge cloud technologies, AI-driven analytics, and secure data platforms.' Healthcare Triangle Inc. remains dedicated to providing updates to shareholders and stakeholders as it continues its focus on enhancing shareholder value. About Healthcare Triangle (HCTI) Healthcare Triangle, Inc. based in Pleasanton, California, reinforces healthcare progress through breakthrough technology and extensive industry knowledge and expertise. We support healthcare, including hospitals and health systems, payers, and pharma/life sciences organizations in their effort to improve health outcomes through better utilization of the data and information technologies that they rely on. Healthcare Triangle achieves HITRUST Certification for Cloud and Data Platform (CaDP), marketed as CloudEz(TM) and DataEz(TM). HITRUST's Risk-based, 2-year (r2) certified status demonstrates to our clients the highest standards for data protection and information security. Healthcare Triangle enables the adoption of new technologies, data enlightenment, business agility, and response to immediate business needs and competitive threats. The highly regulated healthcare and life sciences industries rely on Healthcare Triangle for expertise in digital transformation encompassing the cloud, security and compliance, data lifecycle management, healthcare interoperability, clinical and business performance optimization. Forward-Looking Statements and Safe Harbor Notice All statements other than statements of historical facts included in this press release are 'forward-looking statements' (as defined in the Private Securities Litigation Reform Act of 1995), and include, among others, statements regarding the consummation of the private placement, satisfaction of the customary closing conditions of the private placement and the use of the proceeds therefrom. Such forward-looking statements include our expectations and those statements that use forward-looking words such as 'projected,' 'expect,' 'possibility' and 'anticipate.' The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties, and assumptions, including market and other conditions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors out lined in the company's annual report on form 10-K for the year ended December 31, 2024, on file with the Securities Exchange Commission (the 'SEC') and in previous filings, subsequent filings and future periodic reports filed with the SEC. All the company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. Investors: 1-800-617-9550 [email protected]
Yahoo
03-07-2025
- Business
- Yahoo
Intuitive receives CE mark approval for robotic-assisted surgical system
Intuitive's multi-port robotic-assisted surgical system, da Vinci 5, has secured the CE mark approval for use in both adult and paediatric patients in Europe. This approval allows the system to be utilised for a wide range of minimally invasive endoscopic procedures across abdominopelvic and thoracoscopic procedures, including those in gynaecology, urology, and general laparoscopy. The system builds on the functional design of the da Vinci Xi Surgical System. It features over 150 improvements, contributing to the da Vinci surgical system portfolio that has been leveraged in more than 410,000 procedures in Europe last year. The system delivers improved surgical senses, including Force Feedback-enabled technology and an ergonomic surgeon console for supporting surgeon career longevity. It also streamlines workflow with a universal user interface for care teams and integrates assistance to automate chosen tasks. Additionally, the surgical system delivers actionable insights via an intelligent platform that claims to have 10,000 times more computing power, with new sensors, processors, and software. This provides surgeons with usable data aiding them to quantify, understand, and enhance their surgical performance. Intuitive CEO Dave Rosa said: 'At Intuitive, we're focused on providing healthcare systems across Europe and around the world with thoughtful innovation that solves problems today and into the future. 'After over a decade of careful development, da Vinci 5 is the most advanced and integrated platform we've ever created – designed to enable better outcomes, efficiency, and insights for the future of minimally invasive care.' Last year, da Vinci 5 was cleared by the US Food and Drug Administration for use in various surgical procedures for adults, spanning general, gynaecology, urology, and thoracic. "Intuitive receives CE mark approval for robotic-assisted surgical system" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
29-05-2025
- Business
- Yahoo
NeuroOne to Attend MedInvest's MedTech, AI & Digital Health Conference on June 3-4, 2025
EDEN PRAIRIE, Minn., May 29, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced its participation in the MedInvest MedTech, AI and Digital Health Conference taking place in San Francisco, CA on June 3-4, 2025. Dave Rosa, President and CEO of NeuroOne will be meeting with investors during the two-day event that will feature informative panel discussions, keynote talks and corporate presentations on medical devices, imaging technologies, diagnostics, AI/data analytics and digital health. MedTech, AI & Digital Health ConferenceDates: June 3-4, 2025Location: O'Melveny Conference Center, San Francisco, CAConference registration: The MedInvest Conference is a leading conference series in Healthcare and Life Sciences. MedInvest hosts semiannual conferences in Biotech and Pharma and in MedTech, AI, and Digital Health. To learn more or to register, please visit their website: About NeuroOne NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit IR ContactMZ Group – MZ North AmericaNMTC@ in to access your portfolio
Yahoo
16-05-2025
- Business
- Yahoo
Baird says CEO ‘well-equipped' to further Intuitive Surgical position
After Intuitive Surgical (ISRG) announced this morning that President Dave Rosa will be promoted to Chief Executive Officer, Baird said the firm believes Rosa has long been slated to take over the CEO role, given his 29-plus years at the company. The firm, which expects Rosa to be 'well-equipped to continue to further ISRG's position as a best-in-class MedTech growth story,' keeps an Outperform and $575 price target on Intuitive Surgical shares. Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on ISRG: Disclaimer & DisclosureReport an Issue Intuitive Surgical Appoints David Rosa as CEO Intuitive Surgical announces promotion of Dave Rosa to CEO Wolfpack Research says short UFP Technologies, growth story 'in shambles' Intuitive Surgical Expands Stock Repurchase Program to $4B Intuitive Surgical announces FDA clearance of da Vinci Single Port system